樂
樂觀
樂觀 · 25%SMMT
$32.18
情境價格
$16.090
+0.537 (+3.34%)收盤時
Loading chart…
- 最高
- 16.180
- 開盤
- 15.500
- 成交量加權均價
- 15.78
- 成交量
- 6.25M
- 市值
- 5.52B
- 最低
- 15.060
- 成交金額
- 98.65M
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 0.00
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
AI 分析 of Summit Therapeutics Inc (SMMT)
持有Summit Therapeutics Inc (SMMT) is currently priced at $14.63, which is significantly lower than the analyst price target of $43 from Citi, indicating potential upside. However, the RSI is at a low 25.011, suggesting the stock is oversold and may face further downward pressure in the short term. The company has experienced a 5-day change of -16.83% and a year-to-date change of -16.50%, indicating recent volatility and negative performance. The upcoming earnings report on October 19, 2026, could be a catalyst for movement, but the current financials show significant losses, with a projected EPS of -0.28. Given these factors, while there is potential for recovery, the risks associated with continued losses and market volatility suggest a hold position for now.
分析師評級（6）
上檔空間 +164.08%
買進
6 買進
0 持有
0 賣出
目前: 16.09
最低
18.00
平均
42.49
最高
131.90
Barclays
Equal Weight
$20
2026-10-01
Barclays
2026-10-01
目標價
$20
Equal Weight
Citi
買進
$43
2026-09-29
Citi
2026-09-29
目標價
$43
買進
Jefferies
買進
$25
2026-09-09
Jefferies
2026-09-09
目標價
$25
買進
Bernstein
Market Perform
—
2026-08-25
Bernstein
2026-08-25
目標價
—
Market Perform
Leerink
Market Perform
$13
2026-08-12
Leerink
2026-08-12
目標價
$13
Market Perform
估值指標
Summit Therapeutics Inc（SMMT）目前預期本益比為 3.72，5 年平均預期本益比為 -20.35。
Alphio AI 對 SMMT 的價格情境
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。
持有 SMMT 的大戶
事件時間軸
資訊
9.010-21NewsfilterSummit Therapeutics Launches New Clinical Trial for Biliary Tract Cancer
7.510-05NewsfilterAstraZeneca Invests in Next-Gen Cancer Drug Development
7.510-05CNBCAstraZeneca Invests in New Drug Development Center
- 8.510-05Newsfilter
Summit Therapeutics Secures $2 Billion Investment from AstraZeneca
8.510-03stocktwitsNovartis Partners with Abogen in $7.8 Billion Deal
SMMT 常見問題 —— 由 Alphio AI 解答
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Summit Therapeutics Inc (SMMT) is currently priced at $14.63, which is significantly lower than the analyst price target of $43 from Citi, indicating potential upside. However, the RSI is at a low 25.011, suggesting the stock is oversold and may face further downward pressure in the short term. The company has experienced a 5-day change of -16.83% and a year-to-date change of -16.50%, indicating recent volatility and negative performance. The upcoming earnings report on October 19, 2026, could be a catalyst for movement, but the current financials show significant losses, with a projected EPS of -0.28. Given these factors, while there is potential for recovery, the risks associated with continued losses and market volatility suggest a hold position for now.
6 analysts cover SMMT: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 42.49.
社群
更多 ↗
$SMMT just landed a major combo opportunity for ivonescimab — and Datroway is the key. Summit is teaming with AstraZeneca ($AZN) and Daiichi Sankyo to evaluate ivonescimab with Datroway, a TROP2-targeted ADC jointly developed and commercialized by Daiichi and AstraZeneca. The initial focus is a Phase III study in first-line TNBC, while the collaboration plans to evaluate the combo across multiple solid tumors, including breast and lung cancers. Latest SMMT news here
展開
$SMMT $AZN Citi raised its price target on Summit Therapeutics (SMMT) to $43 from $40 and keeps a Buy rating on the shares after the company announced a $2B investment from AstraZeneca (AZN). AstraZeneca's $2B investment in convertible preferred shares is equivalent to $18.36 per common share, representing a 19% premium to Summit's latest closing price, the analyst tells investors in a research note. Citi views the deal as a "de-risking event" that removes Summit's financing overhang.
展開
Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says. A tidal wave of innovation in biotechnology is improving patient outcomes, transforming the industry's prospects, and lifting long-suffering biotech shares. Spurred by therapeutic breakthroughs and new-product launches, investors have bid up the iShares Biotechnology, or IBB, by 24% this year, while the State Street SPDR S&P Biotech ETF, or XBI, has risen 28%, more than twice the gain of the S&P 500. Large pharmaceutical companies are also paying attention. They have been striking licensing deals with smaller biotechs and scooping up whole companies in a bid to rebuild their pipelines and replace blockbuster drugs facing patent expirations. $MRNA $MRK $RVMD $BMY $SMMT
展開本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。